Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy, Biologic therapy.

Campus Bio-Medico University, Rome, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Rome
Treatments:Chemotherapy, Biologic therapyHospital:Campus Bio-Medico University
Drugs:Journal:Link
Date:Oct 2010

Description:

Patients:
This study involved 48 patients with advanced colorectal cancer whose cancer had progressed following previous standard chemotherapy approaches. The median patient age was 68 (range 31-74) and 47.2% were men.

Treatment:
Patients were treated with a combination of the chemotherapy agent 5-FU/folinic acid and the biologic therapy agent bevacizumab, which is an antibody that blocks a protein involved in cancer cell growth.

Toxicities:
The maximum toxicity level reported was of grade 4. Grade 3 or 4 adverse events included neutropenia (12.5% of patients), diarrhea (20.8%), hypertension (12.5%), and hemorrhaging of the gastrointestinal tract (8.3%) or nose (6.2%).

Results:
The median overall survival in this study was 7.7 months.

Correspondence: Dr. Antonio Russo



Back